Is VTRS or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.79% 20.02% 8.02% Belite Bio N/A -11.84% -11.62%

Does the media prefer VTRS or BLTE?

In the previous week, Belite Bio had 7 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Belite Bio and 1 mentions for Viatris. Viatris' average media sentiment score of 0.86 beat Belite Bio's score of 0.81 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JAZZ or BLTE?

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Belite Bio. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 8 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.81 beat Jazz Pharmaceuticals' score of 0.40 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Belite Bio 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLTE or NBIX?

In the previous week, Neurocrine Biosciences had 10 more articles in the media than Belite Bio. MarketBeat recorded 18 mentions for Neurocrine Biosciences and 8 mentions for Belite Bio. Neurocrine Biosciences' average media sentiment score of 1.42 beat Belite Bio's score of 0.81 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 14 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CORT or BLTE?

In the previous week, Corcept Therapeutics had 12 more articles in the media than Belite Bio. MarketBeat recorded 20 mentions for Corcept Therapeutics and 8 mentions for Belite Bio. Corcept Therapeutics' average media sentiment score of 0.86 beat Belite Bio's score of 0.81 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLTE or ELAN?

In the previous week, Elanco Animal Health had 9 more articles in the media than Belite Bio. MarketBeat recorded 17 mentions for Elanco Animal Health and 8 mentions for Belite Bio. Elanco Animal Health's average media sentiment score of 1.28 beat Belite Bio's score of 0.81 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 16 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Belite Bio (BLTE) Competitors

$193.61 +22.52 (+13.16%)

As of 04:00 PM Eastern

Compare

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Belite Bio stock or one of its competitors? Belite Bio's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Belite Bio compare to Viatris?

Viatris (NASDAQ:VTRS) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Belite Bio had 7 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Belite Bio and 1 mentions for Viatris. Viatris' average media sentiment score of 0.86 beat Belite Bio's score of 0.81 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 3.67%. Belite Bio has a consensus target price of $214.64, suggesting a potential upside of 10.86%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Belite Bio has lower revenue, but higher earnings than Viatris. Belite Bio is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.36	-$3.51B	-$0.36	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

79.9% of Viatris shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Belite Bio	N/A	-11.84%	-11.62%

Viatris has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

Summary

Viatris beats Belite Bio on 8 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Jazz Pharmaceuticals currently has a consensus target price of $285.44, indicating a potential upside of 15.65%. Belite Bio has a consensus target price of $214.64, indicating a potential upside of 10.86%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Jazz Pharmaceuticals is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Jazz Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Belite Bio's net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Belite Bio	N/A	-11.84%	-11.62%

Belite Bio has lower revenue, but higher earnings than Jazz Pharmaceuticals. Belite Bio is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.75	-$356.15M	$14.50	17.02
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Belite Bio. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 8 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.81 beat Jazz Pharmaceuticals' score of 0.40 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Belite Bio	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Jazz Pharmaceuticals beats Belite Bio on 13 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Neurocrine Biosciences?

Belite Bio (NASDAQ:BLTE) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Neurocrine Biosciences has a net margin of 20.91% compared to Belite Bio's net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Belite Bio currently has a consensus price target of $214.64, indicating a potential upside of 10.86%. Neurocrine Biosciences has a consensus price target of $201.05, indicating a potential upside of 29.17%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Neurocrine Biosciences had 10 more articles in the media than Belite Bio. MarketBeat recorded 18 mentions for Neurocrine Biosciences and 8 mentions for Belite Bio. Neurocrine Biosciences' average media sentiment score of 1.42 beat Belite Bio's score of 0.81 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	14 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Neurocrine Biosciences	$2.86B	5.53	$478.60M	$6.82	22.82

Summary

Neurocrine Biosciences beats Belite Bio on 15 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Corcept Therapeutics has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$830.81M	14.52	$99.65M	$0.42	265.76
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Corcept Therapeutics has a net margin of 6.52% compared to Belite Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Belite Bio	N/A	-11.84%	-11.62%

In the previous week, Corcept Therapeutics had 12 more articles in the media than Belite Bio. MarketBeat recorded 20 mentions for Corcept Therapeutics and 8 mentions for Belite Bio. Corcept Therapeutics' average media sentiment score of 0.86 beat Belite Bio's score of 0.81 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics presently has a consensus target price of $138.17, suggesting a potential upside of 23.78%. Belite Bio has a consensus target price of $214.64, suggesting a potential upside of 10.86%. Given Corcept Therapeutics' higher probable upside, equities research analysts plainly believe Corcept Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

Summary

Corcept Therapeutics beats Belite Bio on 13 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Elanco Animal Health?

Belite Bio (NASDAQ:BLTE) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Belite Bio currently has a consensus price target of $214.64, suggesting a potential upside of 10.86%. Elanco Animal Health has a consensus price target of $29.09, suggesting a potential upside of 18.84%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Elanco Animal Health had 9 more articles in the media than Belite Bio. MarketBeat recorded 17 mentions for Elanco Animal Health and 8 mentions for Belite Bio. Elanco Animal Health's average media sentiment score of 1.28 beat Belite Bio's score of 0.81 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	16 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Elanco Animal Health	-3.96%	8.13%	3.99%

Belite Bio has higher earnings, but lower revenue than Elanco Animal Health. Belite Bio is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Elanco Animal Health	$4.72B	2.59	-$232M	-$0.41	N/A

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Summary

Elanco Animal Health beats Belite Bio on 13 of the 16 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLTE vs. The Competition

Export

Metric	Belite Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.80B	$12.17B	$7.17B	$12.88B
Dividend Yield	N/A	2.59%	2.53%	8.57%
P/E Ratio	-70.92	787.21	272.99	25.40
Price / Sales	N/A	759.16	612.73	97.75
Price / Cash	N/A	94.80	77.82	52.27
Price / Book	10.04	12.46	12.85	6.17
Net Income	-$77.61M	$2.82B	$3.47B	$349.50M
7 Day Performance	27.61%	3.80%	1.24%	-0.05%
1 Month Performance	23.11%	6.77%	5.81%	0.80%
1 Year Performance	197.22%	10.44%	25.75%	15.62%

Belite Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLTE Belite Bio	2.3669 of 5 stars	$193.61 +13.2%	$214.64 +10.9%	+169.4%	$7.80B	N/A	N/A	10	News Coverage Analyst Forecast High Trading Volume
VTRS Viatris	2.4351 of 5 stars	$16.68 +0.8%	$17.50 +4.9%	+60.6%	$19.14B	$14.30B	N/A	30,000
JAZZ Jazz Pharmaceuticals	4.087 of 5 stars	$264.07 +3.8%	$272.89 +3.3%	+88.0%	$17.15B	$4.60B	18.22	2,890	Positive News Insider Trade
NBIX Neurocrine Biosciences	4.9439 of 5 stars	$153.09 +0.0%	$200.86 +31.2%	+16.3%	$15.55B	$3.37B	22.43	2,000	Positive News Analyst Forecast
CORT Corcept Therapeutics	4.1797 of 5 stars	$122.64 -0.5%	$138.17 +12.7%	+58.1%	$13.26B	$761.41M	292.00	300	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLTE) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Belite Bio (BLTE) Competitors

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Belite Bio compare to Viatris?

Summary

How does Belite Bio compare to Jazz Pharmaceuticals?

Summary

How does Belite Bio compare to Neurocrine Biosciences?

Summary

How does Belite Bio compare to Corcept Therapeutics?

Summary

How does Belite Bio compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE vs. The Competition

Belite Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Belite Bio (BLTE) Competitors

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Belite Bio compare to Viatris?

Does the media prefer VTRS or BLTE?

Do analysts prefer VTRS or BLTE?

Which has stronger valuation & earnings, VTRS or BLTE?

Do insiders and institutionals hold more shares of VTRS or BLTE?

Is VTRS or BLTE more profitable?

Which has more volatility and risk, VTRS or BLTE?

Summary

How does Belite Bio compare to Jazz Pharmaceuticals?

Do analysts prefer JAZZ or BLTE?

Which has more volatility & risk, JAZZ or BLTE?

Do insiders & institutionals believe in JAZZ or BLTE?

Is JAZZ or BLTE more profitable?

Which has stronger earnings & valuation, JAZZ or BLTE?

Does the media refer more to JAZZ or BLTE?

Summary

How does Belite Bio compare to Neurocrine Biosciences?

Which has more volatility & risk, BLTE or NBIX?

Do institutionals & insiders have more ownership in BLTE or NBIX?

Is BLTE or NBIX more profitable?

Do analysts recommend BLTE or NBIX?

Does the media favor BLTE or NBIX?

Which has better valuation & earnings, BLTE or NBIX?

Summary

How does Belite Bio compare to Corcept Therapeutics?

Do institutionals and insiders hold more shares of CORT or BLTE?

Which has higher earnings and valuation, CORT or BLTE?

Is CORT or BLTE more profitable?

Does the media favor CORT or BLTE?

Do analysts prefer CORT or BLTE?

Which has more volatility and risk, CORT or BLTE?

Summary

How does Belite Bio compare to Elanco Animal Health?

Do analysts rate BLTE or ELAN?

Does the media prefer BLTE or ELAN?

Is BLTE or ELAN more profitable?

Which has preferable valuation and earnings, BLTE or ELAN?

Do institutionals and insiders have more ownership in BLTE or ELAN?

Which has more risk and volatility, BLTE or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE vs. The Competition

Belite Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools